Data as of Jan 23
| +0.53 / +3.52%|
The 2 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 28.75, with a high estimate of 30.00 and a low estimate of 27.50. The median estimate represents a +84.29% increase from the last price of 15.60.
The current consensus among 2 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.